Biomarkers and Genetic Factors Behind Incretin-Pathway Response Response to incretin-pathway compounds tracks with metabolic biomarkers such as fasting glucose, HbA1c, insulin resistance (HOMA-IR), lipids, and CRP
FDA-approved GLP-1 receptor agonists include exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide
The most effective approach includes gradual dose tapering, a protein-rich diet, regular resistance training, consistent lifestyle habits, stress management, and ongoing monitoring
Chronic lung disease in heart failure with preserved ejection fraction In a nationwide cohort study, it was demonstrated that GLP-1 RAs were associated with a reduced risk of cardiopulmonary complications and all-cause mortality compared to non-GLP-1 RAs in patients with T2D and COPD
Our experienced nurse practitioners monitor your progress, adjust treatment as needed, and provide continued guidance throughout your journey